Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996254906> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W1996254906 endingPage "23" @default.
- W1996254906 startingPage "16" @default.
- W1996254906 abstract "Farnesyl protein transferase inhibitors (FTIs) represent a new class of anticancer agents specifically targeting aberrant biologic processes involved with cellular transformation and malignancy. Originally developed to inhibit tumors by preventing activation of oncogenic ras genes via suppression of their posttranslational farnesylation, their anticancer activity appears to stem from their ability to inhibit farnesylation of various proteins that mediate signal transduction, growth, apoptosis, and angiogenesis. The safety, biologic activity, clinical response, and pharmacokinetics of R115777, a potent, orally active FTI, were recently investigated in a phase I dose-ranging study in patients with acute leukemias. Patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML) in blast crisis received R115777 100 mg, 300 mg, 600 mg, 900 mg, or 1,200 mg twice daily for 21 days. Cycles were repeated every 28 to 31 days for up to four cycles. An overall response rate of 29% (1034 evaluable patients) was observed across all R115777 doses. R115777 was well tolerated; common adverse events included fatigue, increased creatinine, nausea, and neutropenia. Dose-limiting toxicity occurred at 1,200 mg twice daily. Farnesylation of lamin A and HDJ-2, examined as biologic end points, was inhibited by R115777 doses ≥ 600 mg twice daily. Pharmacokinetic evaluation suggests that R115777 is concentrated in bone marrow at steady state. The biologic and antitumor activity and favorable tolerability of R115777 support further clinical evaluation alone and in combination therapy in hematologic malignancies." @default.
- W1996254906 created "2016-06-24" @default.
- W1996254906 creator A5040758762 @default.
- W1996254906 date "2001-07-01" @default.
- W1996254906 modified "2023-09-27" @default.
- W1996254906 title "Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies" @default.
- W1996254906 cites W1777794242 @default.
- W1996254906 cites W1884954707 @default.
- W1996254906 cites W1907370866 @default.
- W1996254906 cites W194463696 @default.
- W1996254906 cites W1955547739 @default.
- W1996254906 cites W1974624332 @default.
- W1996254906 cites W2014018734 @default.
- W1996254906 cites W2026834760 @default.
- W1996254906 cites W2034269086 @default.
- W1996254906 cites W2255894651 @default.
- W1996254906 doi "https://doi.org/10.1016/s0037-1963(01)90126-x" @default.
- W1996254906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11523024" @default.
- W1996254906 hasPublicationYear "2001" @default.
- W1996254906 type Work @default.
- W1996254906 sameAs 1996254906 @default.
- W1996254906 citedByCount "52" @default.
- W1996254906 countsByYear W19962549062013 @default.
- W1996254906 countsByYear W19962549062015 @default.
- W1996254906 countsByYear W19962549062016 @default.
- W1996254906 countsByYear W19962549062023 @default.
- W1996254906 crossrefType "journal-article" @default.
- W1996254906 hasAuthorship W1996254906A5040758762 @default.
- W1996254906 hasConcept C126322002 @default.
- W1996254906 hasConcept C181199279 @default.
- W1996254906 hasConcept C2776960273 @default.
- W1996254906 hasConcept C2777827897 @default.
- W1996254906 hasConcept C2778396349 @default.
- W1996254906 hasConcept C2778461978 @default.
- W1996254906 hasConcept C2780007613 @default.
- W1996254906 hasConcept C2780817109 @default.
- W1996254906 hasConcept C502942594 @default.
- W1996254906 hasConcept C55493867 @default.
- W1996254906 hasConcept C57790582 @default.
- W1996254906 hasConcept C71924100 @default.
- W1996254906 hasConcept C86803240 @default.
- W1996254906 hasConcept C98274493 @default.
- W1996254906 hasConceptScore W1996254906C126322002 @default.
- W1996254906 hasConceptScore W1996254906C181199279 @default.
- W1996254906 hasConceptScore W1996254906C2776960273 @default.
- W1996254906 hasConceptScore W1996254906C2777827897 @default.
- W1996254906 hasConceptScore W1996254906C2778396349 @default.
- W1996254906 hasConceptScore W1996254906C2778461978 @default.
- W1996254906 hasConceptScore W1996254906C2780007613 @default.
- W1996254906 hasConceptScore W1996254906C2780817109 @default.
- W1996254906 hasConceptScore W1996254906C502942594 @default.
- W1996254906 hasConceptScore W1996254906C55493867 @default.
- W1996254906 hasConceptScore W1996254906C57790582 @default.
- W1996254906 hasConceptScore W1996254906C71924100 @default.
- W1996254906 hasConceptScore W1996254906C86803240 @default.
- W1996254906 hasConceptScore W1996254906C98274493 @default.
- W1996254906 hasLocation W19962549061 @default.
- W1996254906 hasLocation W19962549062 @default.
- W1996254906 hasOpenAccess W1996254906 @default.
- W1996254906 hasPrimaryLocation W19962549061 @default.
- W1996254906 hasRelatedWork W1460056950 @default.
- W1996254906 hasRelatedWork W1971262694 @default.
- W1996254906 hasRelatedWork W1985986955 @default.
- W1996254906 hasRelatedWork W2060082191 @default.
- W1996254906 hasRelatedWork W2086118286 @default.
- W1996254906 hasRelatedWork W2413724043 @default.
- W1996254906 hasRelatedWork W2430567572 @default.
- W1996254906 hasRelatedWork W3155570094 @default.
- W1996254906 hasRelatedWork W42711520 @default.
- W1996254906 hasRelatedWork W80868084 @default.
- W1996254906 hasVolume "38" @default.
- W1996254906 isParatext "false" @default.
- W1996254906 isRetracted "false" @default.
- W1996254906 magId "1996254906" @default.
- W1996254906 workType "article" @default.